Autor segons l'article: Frentz, Dineke; Van de Vijver, David A M C; Abecasis, Ana B; Albert, Jan; Hamouda, Osamah; Jorgensen, Louise B; Kucherer, Claudia; Struck, Daniel; Schmit, Jean-Claude; Vercauteren, Jurgen; Asjo, Birgitta; Balotta, Claudia; Beshkov, Danail; Camacho, Ricardo J; Clotet, Bonaventura; Coughlan, Suzie; Griskevicius, Algirdas; Grossman, Zehava; Horban, Andrzej; Kolupajeva, Tatjana; Korn, Klaus; Kostrikis, Leondios G; Liitsola, Kirsi; Linka, Marek; Nielsen, Claus; Otelea, Dan; Paraskevis, Dimitrios; Paredes, Roger; Poljak, Mario; Puchhammer-Stockl, Elisabeth; Sonnerborg, Anders; Stanekova, Danica; Stanojevic, Maja; Van Wijngaerden, Eric; Wensing, Annemarie M J; Boucher, Charles A B;SPREAD Programme
Departament: Medicina i Cirurgia
Autor/s de la URV: Vidal Marsal, Francisco
Paraules clau: Updated recommendations Transmission Therapy Surveillance Resistance Prevalence Naive patients Mutations Molecular epidemiology Individuals Hiv-1 Europe Antiretroviral drug-resistance
Resum: Background: One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program.Methods: Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy.Results: The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations remained constant at 5%, a significant decline in protease inhibitors resistance mutations was observed, from 3.9% in 2002 to 1.6% in 2007 (p = 0.001). In contrast, resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) doubled from 2.0% in 2002 to 4.1% in 2007 (p = 0.004) with 58% of viral strains carrying a K103N mutation. Phylogenetic analysis showed that these temporal changes could not be explained by large clusters of TDRM.Conclusion: During the years 2002 to 2007 transmitted resistance to NNRTI has doubled to 4% in Europe. The frequent use of NNRTI in first-line regimens and the clinical impact of NNRTI mutations warrants continued monitoring.
Àrees temàtiques: Zootecnia / recursos pesqueiros Saúde coletiva Odontología Nutrição Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Infectious diseases Farmacia Ensino Engenharias iv Engenharias i Enfermagem Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências ambientais Biotecnología Biodiversidade Astronomia / física
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: francesc.vidal@urv.cat
Identificador de l'autor: 0000-0002-6692-6186
Data d'alta del registre: 2024-09-07
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-14-407
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Bmc Infectious Diseases. 14 (407):
Referència de l'ítem segons les normes APA: Frentz, Dineke; Van de Vijver, David A M C; Abecasis, Ana B; Albert, Jan; Hamouda, Osamah; Jorgensen, Louise B; Kucherer, Claudia; Struck, Daniel; Sch (2014). Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. Bmc Infectious Diseases, 14(407), -. DOI: 10.1186/1471-2334-14-407
DOI de l'article: 10.1186/1471-2334-14-407
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2014
Tipus de publicació: Journal Publications
Repositori URV